AGXT and obesity due to melanocortin 4 receptor deficiency: Holland et al. (2007) demonstrated that in vivo administration of myriocin, a specific SPT inhibitor, improved glucocorticoid, saturated fat, and obesity-induced insulin resistance by inhibiting de novo ceramide synthesis.